Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study
Authors:
- 29 August 2025
- journal article
- Published by Elsevier in The Lancet Oncology
- Vol. 26 (10) , 1334-1345
Abstract
No abstract availableKeywords
Funding Information
- Fellowship from the China Postdoctoral Science Foundation
- Shanghai Sailing Program
- Program of Shanghai Academic Research Leader
- Outstanding Resident Clinical Postdoctoral Program of Zhongshan Hospital Fudan University
- Shanghai Health Commission Clinical Research Special Project
- National Science and Technology Major Project of China
- National Natural Science Foundation of China
- Key Disease Joint Research Program of Xuhui District
This publication has 23 references indexed in Scilit:
- Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinomaNature Communications, 2024
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2023
- Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 studySignal Transduction and Targeted Therapy, 2023
- Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract CancerNEJM Evidence, 2022
- Current and emerging therapies for advanced biliary tract cancersThe Lancet Gastroenterology & Hepatology, 2021
- Tislelizumab uniquely binds to the CC′ loop of PD‐1 with slow‐dissociated rate and complete PD‐L1 blockageFEBS Open Bio, 2021
- Artificial Intelligence and Surgical Decision-makingJAMA Surgery, 2020
- Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 studyThe Lancet Oncology, 2019
- Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic reviewCancer Medicine, 2014
- Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trialThe Lancet Oncology, 2014